Case study: patient-derived clear cell adenocarcinoma xenograft model longitudinally predicts treatment response

Clinical course and molecular profiling of the primary tumor. a Computed tomography scan obtained at the time of diagnosis. The 8.2？×？8.8？cm lobulated metastatic mass in the liver (arrow) and the 8.0？cm centrally necrotic primary tumor mass in the left mesentery (asterisk) are shown. b Representative image of an H&E stained section of the primary tumor. c Copy number count estimates from both exonic (blue) and intragenic or intronic (cyan) reads in Chromosome 17 are shown. d Representative FISH image of the primary tumor using ERBB2/CEP17 dual-color probes. The average ERBB2 signal copy number was 5.1 and the ERBB2/CEP17 ratio was 2.0. e Representative ErbB2 IHC image of the primary tumor. f Sagittal and coronal images of the PET/CT scans before and after treatment with three cycles of paclitaxel and neratinib (second-line treatment). The SUV maximum value for each lesion before and after treatment was, respectively: right lateral abdominal wall musculature, 11.7 and 6.6; posterior 11th rib, 11.2 and 4.1; and the soft tissue abutting the hepatic surgical site, 14.8 and 7.9